Biomarker analyses from JAVELIN Renal 101: Avelumab + axitinib (A+Ax) versus sunitinib (S) in advanced renal cell carcinoma (aRCC).

Toni K. Choueiri,Laurence Albiges,John B. A. G. Haanen,James Larkin,Motohide Uemura,Sumanta K. Pal,Gwenaelle Gravis,Matthew T. Campbell,Konstantin Penkov,Jae-Lyun Lee,Keith A. Ching,Xinmeng Jasmine Mu,Xiao Wang,Weidong Zhang,Jing Wang,Aleksander Chudnovsky,Alessandra di Pietro,Paul B. Robbins,Robert J. Motzer

Biomarker analyses from JAVELIN Renal 101: Avelumab + axitinib (A+Ax) versus sunitinib (S) in advanced renal cell carcinoma (aRCC).

2019

Toni K. Choueiri
Laurence Albiges
John B. A. G. Haanen
James Larkin
Motohide Uemura
Sumanta K. Pal
Gwenaelle Gravis
Matthew T. Campbell
Konstantin Penkov
Jae-Lyun Lee
Keith A. Ching
Xinmeng Jasmine Mu
Xiao Wang
Weidong Zhang
Jing Wang
Aleksander Chudnovsky
Alessandra di Pietro
Paul B. Robbins
Robert J. Motzer

101Background: The phase 3 JAVELIN Renal 101 trial in previously untreated patients (pts) with aRCC demonstrated a progression-free survival (PFS) benefit and higher objective response rate with A+...

Keywords:

Avelumab
Renal cell carcinoma
Biomarker (medicine)
Axitinib
Pathology
Oncology
Javelin
Sunitinib
Medicine
Internal medicine
objective response

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations